top of page

RVNC

Revance Therapeutics

Price

chg

chg neg

quotes and stock data may be delayed 15 minutes

 My Notes

Only BPIQ Pro members can create company notes. Learn more here.

52 wk low

low api

52 wk hi

high api

Cash

$262.6M

Burn Rate (Qtr)

$61.3M

Mkt Cap

mkt cap api

Avg Volume

volume api

*cash/burn updated:

Q1 '22

Drug Pipeline

Click the button to see the updated pipeline

No drug found

We don't have any drug data for this company yet

Drug | Disease (links)

Stage (next event)

Catalyst Date

Drug Name

Indication

Phase

Event

Exp Date

A free account is required to see the catalyst dates, notes, and more!

Loading Catalysts...

search in progress

Pipeline powered by

RVNC

BPIQ_Logo_RGB-01.jpg

Company Profile

Revance is a biotechnology company focused on innovative aesthetic and therapeutic offerings. We recently expanded our aesthetics portfolio to include digital services with the acquisition of an innovative fintech platform. We have assembled a team of motivated, talented professionals who collectively aim to transform patient experiences and disrupt the status quo. Exceptional talents with passion, creativity, and dedication to improving lives will immediately contribute to our ambitious pipeline and unique culture. Our employees work on challenging projects in a supportive environment that provides opportunities for growth and development.

Recent Posts

See what the community is saying - click to see full post.

September 2022 Big Mover™ Stocks and Movers to Watch Report

Biotech PDUFAs to Watch September 2022 - RVNC, OBSV, BLUE

Q1 '22 Perceptive Newly Added Stocks (hedge fund)

J.P. Morgan Healthcare Conference

bottom of page